HRAS G12V
|
Thyroid Gland Carcinoma
|
HRAS G12V
|
Thyroid Gland Carcinoma
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
HRAS G12V
|
Head and Neck Cancer
|
HRAS G12V
|
Head and Neck Cancer
|
erlotinib Resistant: D – Preclinical
|
erlotinib Resistant: D – Preclinical
|